Pharmexa and BN ImmunoTherapeutics enter license agreement
Under the new agreement, BN ImmunoTherapeutics will develop a new therapeutic vaccine against breast cancer combining the technologies of the two companies. The agreement includes milestone payments and a royalty on sales to Pharmexa if the project is successful. Further financial details from the collaboration are not disclosed
Bavarian Nordic's cancer therapy approach is to develop vaccines targeting both the humoral (antibody) and cellular arm of the immune system. The MVA-BN vector will transport the HER-2 DNA AutoVac(TM) molecule into the immune cells, which then start a killer cell and antibody based immune response against breast cancer cells expressing the HER-2 protein. Bavarian Nordic has previously demonstrated the MVA-BN vector's ability to generate immune responses. The inclusion of the AutoVac(TM) technology is expected to increase the immunogenicity and thus the effectiveness of the vaccine, even further.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.